I've been waiting for them to go public! I think rkrw was following them noticed he doesn't post here much maybe he'll post some of his thoughts? I'll have to start doing a lot more DD and look for a good price. I think they have 3 drugs that will go against Genzyme including their bread and butter (Cerezyme).
Hmmm not the best symbol for a stock but I still like the company :). 86.25 million no way this is the full cap. Even a tiny penetration of Cerazyme should be worth a pretty penny. I have to do more research but I got the sense Genzyme's Pompe drug left a lot to be desired and that is one of the larger lysosomal diseases. Amicus is in Phase 1 but this could potential be a huge drug too! The Fabry drug is oral I believe which would be an advantage over TKT (Shire's) and Genzyme's but I don't know much about its efficacy.
WASHINGTON, March 30 (Reuters) - Biopharmaceutical firm Amicus Therapeutics Inc. said on Friday it is planning an initial public offering of as much as $86.25 million in common stock.
Morgan Stanley, Merrill Lynch & Co., JPMorgan, Lazard Capital Markets and Pacific Growth Equities LLC, according to a preliminary offering document filed with the U.S. Securities and Exchange Commission.
It is seeking a Nasdaq listing under the symbol "FOLD."
Amicus- This is their 2nd time. In August 2006, due to market conditions, the Company withdrew its IPO. At least for the AT2101 molecule (treatment for Gaucher disease), they will compete with PLX too.
News 
Market Data 
Discover 
